论文部分内容阅读
目的观察力尔凡联合化疗治疗恶性胸腔积液的临床疗效和毒副反应。方法采用随机单盲研究方法,恶性胸腔积液42例患者随机分成联合治疗组和对照组。联合治疗组胸腔注射DDP 40 mg+力尔凡30 mg,分别溶于20 m l、10 m l的生理盐水中,对照组胸腔内注射DDP 40 mg,溶于20 m l的生理盐水中,每周一次,2~3周为一疗程,一个月后进行疗效评价。结果联合治疗组和对照组各21例,联合治疗组有效率(PR+CR)85.7%,对照组有效率(PR+CR)52.3%。两组比较有显著性差异(P<0.05)。毒副反应:联合治疗组白细胞减少(4.8%),低于对照组白细胞减少6例(28.6%),有显著性差异(P<0.05)。结论力尔凡与顺铂合用治疗恶性胸腔积液临床疗效好,毒副反应低,是一种较为理想的临床方案。
Objective To observe the clinical efficacy and side effects of Rievan combined with chemotherapy in the treatment of malignant pleural effusion. Methods A randomized single-blind study was conducted. Forty-two patients with malignant pleural effusion were randomly divided into combined treatment group and control group. The combined treatment group received intrapleural injection of DDP 40 mg + nirvan 30 mg dissolved in 20 ml of 10 ml normal saline. The control group received intrapleural DDP 40 mg dissolved in 20 ml of normal saline once a week for 2 ~ 3 weeks for a course of treatment, a month after the efficacy evaluation. Results The combination therapy group and the control group had 21 cases each. The effective rate (PR + CR) of the combination therapy group was 85.7% and that of the control group (PR + CR) was 52.3%. There was significant difference between the two groups (P <0.05). Toxicities: Leukopenia (4.8%) in the combined treatment group was lower than that in the control group (6 cases, 28.6%), with significant difference (P <0.05). Conclusion Li Erfan combined with cisplatin in the treatment of malignant pleural effusion with good clinical efficacy and low toxicity, is an ideal clinical program.